Core Prevention Measures
These measures apply to anyone in or returning from a region with an active Ebola outbreak. For the 2026 DRC outbreak, CDC has a Level 4 (avoid all travel) notice for Ituri and North Kivu provinces, Level 3 (reconsider nonessential travel) for Haut-Uélé and Tshopo, and Level 2 (enhanced precautions) for the rest of DRC and Uganda (CDC, September 2026).
🧼 Hand Hygiene
Hand hygiene is the foundation of every other precaution:
- Wash hands frequently with soap and water for at least 20 seconds
- Use alcohol-based hand rub when soap and water are unavailable — CDC's infection-control guidance accepts either, but requires soap and water when hands are visibly soiled
- Wash hands before eating, after using the toilet, and after any contact with others
- Avoid touching your eyes, nose, or mouth with unwashed hands
Ebola is an enveloped virus — alcohol-based hand rubs inactivate it.
🚫 Avoid High-Risk Contact
Ebola is transmitted only through direct contact with infectious body fluids:
- Do not touch or care for sick individuals without proper PPE
- Avoid physical contact with anyone who has died from suspected or confirmed Ebola
- Do not participate in traditional funeral or burial practices involving washing or touching the body
- Avoid healthcare facilities in outbreak areas unless essential — hospitals can be amplification sites during outbreaks
🦇 Avoid Animal Contact
Every Ebola outbreak begins with an animal-to-human spillover event:
- Do not handle, butcher, or consume bushmeat (wild animals, particularly bats and primates) in affected regions
- Avoid caves and forests known to harbor fruit bat colonies in outbreak-affected countries
- Do not handle sick or dead animals
- Cook all meat thoroughly — the virus is inactivated by proper cooking temperatures
🧤 PPE for Caregivers
Anyone providing care to a potentially Ebola-infected individual needs full barrier protection:
- Fluid-resistant or impermeable gown
- Double nitrile gloves
- N95 respirator or PAPR
- Full face shield or goggles
- Head cover and boot covers
PPE is only as effective as the training behind it. CDC's hospital guidance requires adequate space for donning and doffing, a log of everyone entering the room, and recommends posting personnel at the door to check PPE use.
What Actually Reduced Transmission — the Evidence Behind Each Measure
CDC's and WHO's prevention pages list the measures. They do not say how much each one mattered. The outbreak studies do.
Safe Burial: the Single Largest Measured Effect
The clearest quantitative evidence comes from transmission-chain data. Robert et al. (American Journal of Epidemiology 2019) analysed 860 cases in 129 chains of transmission from the second half of the Guinea epidemic. Unsafe burial was associated with 1.82 times as many secondary cases (incidence rate ratio 1.82, 95% CI 1.10–3.02). The 2007 Bundibugyo outbreak in Uganda — the species now circulating — pointed the same way from a much smaller base: Wamala et al. (Emerging Infectious Diseases 2010) found most transmission was associated with handling of the dead without protection, with an adjusted odds ratio of 3.83 (95% CI 1.78–8.23).
This is why the 2026 response tracks burials as a control indicator. CDC's operational review found that as of August 21, 2026, only 49% of affected health zones had a safe-and-dignified-burial team (target: 100%) and 59% of confirmed deaths were occurring outside a treatment unit (target: 0%) — the deaths most likely to involve an unsafe burial (CDC MMWR 2026;75(35):554).
Isolation and Treatment Units: Fewer Onward Infections Even When the Patient Dies
In the same Guinea analysis, attending an Ebola treatment unit was associated with a 38% reduction in secondary cases among patients who did not survive (IRR 0.62, 95% CI 0.38–0.99). The mechanism is not mysterious — a patient in an isolation ward is not being nursed at home by relatives without gloves — but the number is worth having, because it means isolation protects the community even when it cannot save the patient. The study also found that children transmitted far less than adults (IRR 0.35, 95% CI 0.21–0.57) and that the first generation of each chain produced more secondary cases (mean 1.77) than later generations (0.70), consistent with control measures taking hold once a chain is recognised.
Contact Tracing and the 21-Day Rule
Contact tracing works for Ebola because people are not infectious before symptoms (CDC; WHO) and because the incubation period is bounded: the WHO Ebola Response Team's NEJM analysis of the 2014 epidemic found a mean incubation of 11.4 days with about 95% of cases developing symptoms within 21 days. The 2026 numbers show what that means operationally. As of September 7, 2026, DRC had 24,719 contacts requiring daily follow-up, of whom 85.3% were seen in the previous 24 hours (WHO DON 617). CDC's indicator review found an average of only 10.6 contacts identified per confirmed case against a target of 20 or more, and that only 15–20% of new cases had been previously listed as contacts against a target above 90% — meaning most new cases were arising outside known chains (CDC MMWR 2026;75(35):554). Those two figures are the difference between an outbreak that is being traced and one that is being followed.
Vaccination — What Ring Vaccination Achieved Against Zaire Virus
The Guinea ring vaccination trial (Henao-Restrepo et al., The Lancet 2017) is the reason Ervebo exists. Contacts and contacts-of-contacts of confirmed cases were enrolled in "rings"; rings were randomised to immediate or delayed (21-day) vaccination. Among the 4,539 people in immediately vaccinated rings, no cases of Ebola occurred 10 or more days after randomisation, versus 16 cases in the delayed rings — vaccine efficacy 100% (95% CI 68.9–100, p=0.0045). Across all 117 rings including the non-randomised ones, the comparison was 0 versus 23 cases (95% CI 79.3–100). The lower bound of the confidence interval — 68.9% — is the honest floor; "100% effective" is the point estimate of a trial that recorded 16 events.
None of this transfers automatically to the 2026 outbreak, because the vaccine's glycoprotein is Zaire ebolavirus's, and the outbreak is Bundibugyo virus. See the next section.
Vaccination in the 2026 Outbreak: What Is and Is Not Known
Three facts from primary sources, in order of certainty:
- Ervebo's approval does not cover Bundibugyo virus. FDA's indication is "the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older" (FDA, content current as of April 21, 2026). CDC's clinical guidance (May 27, 2026) states that Ervebo "does not provide protection against other species of orthoebolaviruses" and that there are no FDA-approved vaccines for Bundibugyo, Sudan or Taï Forest virus.
- WHO has reviewed the evidence twice and declined to recommend routine use. On August 7, 2026 WHO's Technical Advisory Group on candidate vaccine prioritisation recommended Ervebo be prioritised for a randomised trial in the outbreak. On August 19, WHO's Strategic Advisory Group of Experts on Immunization (SAGE) concluded that "available evidence remains insufficient to support the programmatic use of Ervebo for the prevention of BVD, and that its efficacy against BVD in humans remains unknown," recommending use only within a research protocol (WHO DON 617).
- Vaccination under that protocol has begun. Ervebo vaccination of health and frontline workers started on August 27, 2026 in Kisangani, Tshopo; as of September 6, 2026, 2,007 people had been vaccinated across six health zones in Tshopo, Bas-Uélé and Ituri (WHO DON 616 and 617). WHO's own wording is that "it is not known whether it provides protection against the Bundibugyo virus in humans."
Bundibugyo-specific vaccines. The only Bundibugyo-specific vaccine in human trials on ClinicalTrials.gov (checked September 14, 2026) is NCT07737717, a Phase 1 placebo-controlled study of Moderna's mRNA-1469 in 84 healthy adults aged 18–65 at three sites in Canada; it began July 31, 2026 and lists an estimated completion date of September 30, 2027. A Phase 1 safety study cannot tell anyone whether the vaccine prevents disease, and its timeline places any efficacy answer well beyond the current outbreak's likely course. Not known: whether Ervebo provides any cross-protection against Bundibugyo virus in people. That is the question the research-protocol vaccination is designed to answer, and no result has been published.
Surface Disinfection
Ebola virus can survive on surfaces and objects contaminated with infectious body fluids. Proper disinfection of any surfaces that may have been in contact with a sick individual is essential in care settings.
What Kills Ebola on Surfaces
Ebola is an enveloped virus and is relatively susceptible to standard disinfectants. The following are effective per CDC guidance:
- EPA-registered hospital disinfectants — CDC's hospital guidance for viral hemorrhagic fevers specifies a product from EPA's List Q (products from List L may also be used for Ebola), used according to the label's concentration and contact time (CDC environmental infection control guidance, May 2024)
- Diluted household bleach — a long-standing field standard; follow the product label or the response's infection-control protocol for the dilution rather than a remembered ratio
- Alcohol solutions (≥70% isopropyl or ethanol) — effective for hard surfaces and skin
- Heat — autoclaving and steam sterilization inactivate the virus
All soiled materials — bedding, clothing, disposable PPE — are Category A infectious waste in the United States and must be handled under the interagency guidance CDC links from the same page. CDC also requires the PPE doffing area itself to be cleaned at least daily and after any grossly contaminated doffing, by a worker wearing clean PPE.
After Potential Exposure: 21-Day Monitoring
The incubation period for Ebola is 2–21 days. Anyone with a potential exposure must monitor their health for 21 days from the last possible exposure date.
Self-Monitoring Protocol
- Take your temperature daily (CDC asks travelers who were in DRC to check every day and again whenever they feel unwell)
- Record results — alert your healthcare provider or public health authority if temperature reaches ≥38°C (100.4°F), CDC's threshold
- Watch for: fever or feeling feverish, headache or body aches, rash, weakness or tiredness, sore throat, diarrhea, vomiting, stomach pain, or unexplained bleeding or bruising (CDC's returning-traveler list, September 11, 2026)
- If symptoms develop, the CDC recommends isolating immediately and calling your healthcare provider or emergency services before traveling anywhere — do not take public transportation to a healthcare facility
- Inform them of your potential exposure history so appropriate infection control measures can be taken before you arrive
For people with a high-risk exposure — skin or mucous-membrane contact with a patient's fluids, direct contact with a patient, a PPE breach, or living in the same household — CDC's guidance is stricter: quarantine, daily monitoring, and no commercial travel until 21 days after the last exposure (CDC infection-control guidance, June 24, 2026).
How Prevention Is Measured in a Live Outbreak — CDC's Five Indicators
Prevention at the population level is a set of operational targets. CDC published them for the 2026 DRC response, with the status as of August 21, 2026. No consumer page summarises this.
| Domain | Indicator | Target | Status, Aug 21, 2026 |
|---|---|---|---|
| Case detection | Alerts investigated within 24 hours | >90% | 83% (last reported Aug 5) |
| Contact tracing | Contacts identified per confirmed case | ≥20 | 10.6 |
| Daily contact-tracing completeness | >95% | 82% | |
| New cases that were known contacts | >90% | 15–20% (last reported Jul 12) | |
| Laboratory | Validated alerts tested | >90% | 72% |
| Test positivity | 0% | 24% | |
| Isolation | Treatment-unit bed occupancy | <80% | 64% nationally; up to 140% in some zones |
| Confirmed cases isolated within 24 h | >90% | No data | |
| Safe burial | Confirmed deaths occurring outside a treatment unit | 0% | 59% |
| Affected health zones with a safe-burial team | 100% | 49% | |
| Deaths receiving a safe and dignified burial | 100% | No data |
Two of the eleven indicators had no data at all, and two more had not been reported for weeks. That is itself a finding: in this outbreak the response cannot fully measure the two things — prompt isolation and safe burial — that the transmission-chain evidence says matter most.
Compared to what? For how Ebola's exposure, hospitalisation and death rates compare with 14 other viruses, see the Virus Risk Perspective and this site's Ebola risk perspective.
Frequently Asked Questions
Can Ebola be prevented?
Yes. Because Ebola does not spread through the air, basic barrier precautions — hand hygiene, PPE, and avoiding direct contact with body fluids of infected individuals — are highly effective. Avoiding bushmeat and unsafe burial practices addresses the two main transmission pathways at the population level; in Guinea, unsafe burial was associated with 1.82 times as many onward infections and treatment-unit care cut onward transmission from patients who died by 38% (Robert et al., 2019). In healthcare settings, consistent PPE use is the key intervention.
Does hand sanitizer kill Ebola?
Yes. Ebola is an enveloped virus, meaning its outer membrane is disrupted by alcohol. CDC's infection-control guidance for viral hemorrhagic fevers accepts either soap and water or alcohol-based hand rub, and requires soap and water when hands are visibly soiled.
Is there an Ebola prevention vaccine?
Yes, for Zaire ebolavirus only. Ervebo (rVSV-ZEBOV) showed 100% efficacy (95% CI 68.9–100) in the Guinea ring vaccination trial (Henao-Restrepo et al., The Lancet 2017) and is FDA-approved for people 12 months and older. The Zabdeno/Mvabea prime-boost regimen (Janssen) was approved in the EU in 2020 but its marketing authorisations were withdrawn at the company's request on May 1, 2026 and it was never marketed (EMA), leaving Ervebo as the only licensed Ebola vaccine. Neither is approved or established against Bundibugyo virus, the species behind the 2026 DRC outbreak. WHO's SAGE concluded on August 19, 2026 that the evidence is insufficient to recommend Ervebo for Bundibugyo virus outside a research protocol; 2,007 health and frontline workers had been vaccinated under that protocol as of September 6, 2026 (WHO DON 617). The only Bundibugyo-specific vaccine in human trials is a Phase 1 study of Moderna's mRNA-1469 in 84 adults in Canada that began July 31, 2026 (ClinicalTrials.gov NCT07737717).
What kills the Ebola virus on surfaces?
An EPA-registered hospital disinfectant from EPA's List Q (or List L for Ebola), used according to its label, is CDC's specification for hospitals. Diluted bleach and alcohol solutions (≥70%) also inactivate the virus, as do heat, UV light, and autoclaving. Because Ebola is an enveloped virus, it is less environmentally stable than non-enveloped viruses and is more susceptible to most standard disinfectants.
Related Topics
Transmission
How Ebola spreads — and how it does not spread.
Read more →For HCWs
Full PPE requirements and the 2026 health-worker infection counts.
Read more →Travel Risk
CDC Level 4 notice for Ituri and North Kivu — and the U.S. entry rules.
Read more →2026 Outbreak
Active DRC outbreak — Bundibugyo virus, no approved vaccine.
Read more →Sources & References
- Centers for Disease Control and Prevention. Ebola Disease Basics. Page dated June 2, 2026. cdc.gov/ebola/about
- Centers for Disease Control and Prevention. Infection Prevention and Control Recommendations for Patients in U.S. Hospitals who are Suspected or Confirmed to have Selected Viral Hemorrhagic Fevers. Page dated June 24, 2026. cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control
- Centers for Disease Control and Prevention. Environmental Infection Control for VHFs in U.S. Hospitals. Page dated May 3, 2024. cdc.gov/viral-hemorrhagic-fevers/hcp/infection-control/environmental-infection-control-hospitals
- Centers for Disease Control and Prevention. Information for Travelers Returning from Ebola-Affected Areas. Page dated September 11, 2026. cdc.gov/ebola/situation-summary/returning-travelers
- Centers for Disease Control and Prevention. Clinical Guidance for Ebola Disease. Page dated May 27, 2026. cdc.gov/ebola/hcp/clinical-guidance
- Kabasele D, et al. Notes from the Field: Characteristics and Monitoring of the 2026 Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo, August 2026. MMWR Morb Mortal Wkly Rep 2026;75(35):554–556. doi:10.15585/mmwr.mm7535e1
- World Health Organization. Ebola disease — fact sheet. Updated May 2026. who.int/news-room/fact-sheets/detail/ebola-disease
- World Health Organization. Disease Outbreak News 616 (August 28, 2026) and 617 (September 10, 2026): Ebola disease caused by Bundibugyo virus — Democratic Republic of the Congo. who.int/…/2026-DON617
- U.S. Food and Drug Administration. ERVEBO. Content current as of April 21, 2026. fda.gov/vaccines-blood-biologics/ervebo
- Henao-Restrepo AM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet 2017;389:505–518. doi:10.1016/S0140-6736(16)32621-6
- Robert A, et al. Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic. Am J Epidemiol 2019;188(7):1319–1327. doi:10.1093/aje/kwz090
- Wamala JF, et al. Ebola hemorrhagic fever associated with novel virus strain, Uganda, 2007–2008. Emerg Infect Dis 2010;16(7):1087–92. doi:10.3201/eid1607.091525
- WHO Ebola Response Team. Ebola virus disease in West Africa — the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371:1481–95. doi:10.1056/NEJMoa1411100
- ClinicalTrials.gov. NCT07737717: A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease. Record last updated September 10, 2026. clinicaltrials.gov/study/NCT07737717
